ESI-09

SKU: orb1305922

Description

ESI-09 is a non-cyclic nucleotide antagonist of EPAC proteins, exhibiting IC₅₀ values of 3.2 μM for EPAC1 and 1.4 μM for EPAC2. This tool compound is utilized in vitro to investigate cAMP/EPAC signaling pathways in diabetes, cancer, and neurological disorders research.

Research Area

Infectious Disease & Virology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 263707-16-0
• MW: 330.77
• Purity: 98.48%
• Formula: C₁₆H₁₅ClN₄O₂
• SMILES: CC(C)(C)c1cc(no1)C(=O)C(=NNc1cccc(Cl)c1)C#N
• Target: cAMP,Virus Protease
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.05 mM);Ethanol:6.6 mg/mL (19.95 mM);DMSO:33.1 mg/mL (100.07 mM)

Bioactivity

• Target IC50:
  EPAC2:1.4 μM|EPAC1:3.2 μM
• In Vivo:
  ESI-09 specifically inhibits intracellular EPAC-mediated activation of Rap1 and phosphorylation of Akt, as well as EPAC-mediated secretion in pancreatic β-cells. In pancreatic cancer cells induced by 007-AM, ESI-09 reduces cell adhesion and inhibits cell migration. In Schwann cells stimulated by CPT-cAMP, ESI-09 significantly suppresses cell differentiation and myelination. Additionally, in SC neuronal cultures, ESI-09 notably decreases the number of O1-positive and MBP-positive cells.
• In Vitro:
  In WT C57BL/6 mice, ESI-09 (10 mg/kg/d, i.p.) prevents SFG Rickettsiosis by inhibiting EPAC1.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

VirusProtease, Virus Protease, Inhibitor, ESI 09, ESI09, ESI-09, EPAC1, EPAC2, inhibit

Compound Identifiers

PubChem CID

2744921